Health Advisory Council Newsletter | Fall 2019 | New Members

New Member Spotlight

Please join us in welcoming the Health Advisory Council’s newest members, AbbVie, FDA MedWatch, and Greenwich Biosciences! We’ve asked them to introduce themselves.


AbbVie is a research-driven biopharmaceutical company headquartered in the greater Chicago area. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We also go beyond medicine to deliver innovative, holistic health care solutions to patients. For example, in 2018 we offered 90 patient support programs in the U.S., resulting in more than 81,000 U.S. patients receiving AbbVie medicine at no cost.

We hope to learn more about National Consumer League’s health priorities & programs, and we hope to identify & advance common policy priorities to safeguard the health of American consumers and families. Areas of potential interest include improving patient adherence, protecting Americans from counterfeit drugs, and preventing fraud & misuse of important health programs like the 340B Drug Discount Program.

FDA MedWatch

Beth Fritsch and Steve Morin of FDA’s Office of the Commissioner, Office of External Affairs Stakeholder Engagement are working to proactively build strong external relationships with Health Professional Organizations, Consumer Groups, Trade Associations, Patient Advocacy Organizations, Think Tanks, and other stakeholders to better inform our policy making process. We are joining the Health Advisory Council to network with like-minded groups so we can identify and better understand consumer needs and improve how we educate and inform the public. Learn more about FDA MedWatch.

Greenwich Biosciences

Greenwich Biosciences is focused on discovering, developing, and commercializing novel therapeutics from its propriety cannabinoid product platform. Our enduring commitment to scientific rigor and exacting pharmaceutical manufacturing standards enables us to bring forward plant-derived cannabinoid prescription medicines for patients. We are the first and only company to pursue and receive FDA approval for a plant-derived cannabinoid therapy that addresses difficult-to-treat conditions with significant unmet needs. It is our passion and purpose to continually seek solutions that transform the lives of those living with rare and severe neurological diseases.

GW looks forward to better understanding the level of consumer knowledge, questions and concerns regarding cannabis and CBD products, and to share our knowledge and expertise in ways that promote consumer health and safety. For additional information, please visit